Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2019, Article ID 5635269, 10 pages
https://doi.org/10.1155/2019/5635269
Research Article

Synthesis and Evaluation of 18F-Labeled Peptide for Gonadotropin-Releasing Hormone Receptor Imaging

Nanfang PET Center, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, Guangdong 510515, China

Correspondence should be addressed to Kongzhen Hu; moc.361@ssalgnots

Received 28 November 2018; Revised 23 January 2019; Accepted 29 January 2019; Published 7 March 2019

Academic Editor: Reza Vali

Copyright © 2019 Shun Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. V. Schally, A. Arimura, A. J. Kastin et al., “Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones,” Science, vol. 173, no. 4001, pp. 1036–1038, 1971. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Gründker and G. Emons, “The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis,” Frontiers in Endocrinology, vol. 8, pp. 1–10, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Leuschner and W. Hansel, “Targeting breast and prostate cancers through their hormone receptors1,” Biology of Reproduction, vol. 73, no. 5, pp. 860–865, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Bjelobaba, S. S. Stojilkovic, and Z. Naor, “Editorial: gonadotropin-releasing hormone receptor signaling and functions,” Frontiers in Endocrinology, vol. 9, pp. 10–12, 2018. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Dufau, “The luteinizing hormone receptor,” Annual Review of Physiology, vol. 60, no. 1, pp. 461–496, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Nagy and A. V. Schally, “Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers1,” Biology of Reproduction, vol. 73, no. 5, pp. 851–859, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. Å. Tieva, P. Stattin, P. Wikström, A. Bergh, and J.-E. Damber, “Gonadotropin-releasing hormone receptor expression in the human prostate,” The Prostate, vol. 47, no. 4, pp. 276–284, 2001. View at Publisher · View at Google Scholar
  8. M. Fekete, A. Zalatnai, A. M. Comaru-schally, and A. V. Schally, “Membrane receptors for peptides in experimental and human pancreatic cancers,” Pancreas, vol. 4, no. 5, pp. 521–528, 1989. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Gründker, P. Völker, F. Griesinger et al., “Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice,” American Journal of Obstetrics and Gynecology, vol. 187, no. 3, pp. 528–537, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. T. M. Bateman, “Advantages and disadvantages of PET and SPECT in a busy clinical practice,” Journal of Nuclear Cardiology, vol. 19, no. S1, pp. 3–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Flanagan, B. J. Fromme, J. S. Davidson, and R. P. Millar, “A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH Receptors1,” Endocrinology, vol. 139, no. 10, pp. 4115–4119, 1998. View at Publisher · View at Google Scholar
  12. H. Gali, T. J. Hoffman, G. L. Sieckman, N. K. Owen, K. V. Katti, and W. A. Volkert, “Synthesis, characterization, and labeling with99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent,” Bioconjugate Chemistry, vol. 12, no. 3, pp. 354–363, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Barda, N. Cohen, V. Lev et al., “Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer,” Nuclear Medicine and Biology, vol. 31, no. 7, pp. 921–933, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Schottelius, S. Berger, T. Poethko, M. Schwaiger, and H.-J. Wester, “Development of Novel68Ga- and18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency,” Bioconjugate Chemistry, vol. 19, no. 6, pp. 1256–1268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. R. Jalilian, S. Shanehsazzadeh, M. Akhlaghi et al., “Development of [111In]-DTPA-buserelin for GnRH receptor studies,” Radiochim Acta, vol. 98, pp. 113–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Guo, J. Lu, H. Hathaway, M. E. Royce, E. R. Prossnitz, and Y. Miao, “Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides,” Bioconjugate Chemistry, vol. 22, no. 8, pp. 1682–1689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Zoghi, A. R. Jalilian, A. Niazi, F. Johari-daha, B. Alirezapour, and S. Ramezanpour, “Development of a 68Ga-peptide tracer for PET GnRH1-imaging,” Annals of Nuclear Medicine, vol. 30, no. 6, pp. 400–408, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Xu, C. Feng, and Y. Miao, “Evaluation of novel 111 In-labeled gonadotropin-releasing hormone peptides for human prostate cancer imaging,” Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 20, pp. 4647–4651, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Lee, J. C. Paeng, S. J. Lee et al., “Comparison of diagnostic sensitivity and quantitative indices between 68Ga-DOTATOC PET/CT and 111in-pentetreotide SPECT/CT in neuroendocrine tumors: a preliminary report,” Nuclear Medicine and Molecular Imaging, vol. 49, no. 4, pp. 284–290, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Karten and J. E. Rivier, “Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective,” Endocrine Reviews, vol. 7, no. 1, pp. 44–66, 1986. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Beckers, M. Bernd, B. Kutscher, R. Kühne, S. Hoffmann, and T. Reissmann, “Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor,” Biochemical and Biophysical Research Communications, vol. 289, no. 3, pp. 653–663, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Liu, H. Liu, G. Ren, R. H. Kimura, J. R. Cochran, and Z. Cheng, “PET imaging of integrin positive tumors using 18F labeled knottin peptides,” Theranostics, vol. 1, pp. 403–412, 2011. View at Publisher · View at Google Scholar
  23. K.-Z. Hu, H. Wang, G. Tang et al., “Automated synthesis of symmetric integrin αvβ3-targeted radiotracer [18F]FP-PEG3-β-Glu-RGD2,” Journal of Radioanalytical and Nuclear Chemistry, vol. 299, no. 1, pp. 271–276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Hachem, M. Tiberi, B. Ismail et al., “Characterization of 18F-FPyKYNE-Losartan for imaging AT1 receptors,” Journal of Nuclear Medicine, vol. 57, no. 10, pp. 1612–1617, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Feng, H. Wen, X. Ju et al., “Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC),” Journal of Ovarian Research, vol. 10, no. 1, pp. 1–8, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. S. V. Liu, A. V. Schally, D. Hawes et al., “Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists,” Clinical Cancer Research, vol. 16, no. 18, pp. 4675–4680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. W.-H. Yang, M. Wieczorck, M. C. Allen, and T. M. Nett, “Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors,” Endocrinology, vol. 144, no. 4, pp. 1456–1463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Schally and A. Nagy, “Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors,” European Journal of Endocrinology, vol. 141, pp. 1–14, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. S. C. Penchala, M. R. Miller, A. Pal et al., “A biomimetic approach for enhancing the in vivo half-life of peptides,” Nature Chemical Biology, vol. 11, no. 10, pp. 793–798, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. N. V. Nukolova, H. S. Oberoi, Y. Zhao, V. P. Chekhonin, A. V. Kabanov, and T. K. Bronich, “LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer,” Molecular Pharmaceutics, vol. 10, no. 10, pp. 3913–3921, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Eicke, A. R. Günthert, G. Emons, and C. Gründker, “GnRH-II agonist [d-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells,” International Journal of Oncology, vol. 29, pp. 1223–1229, 2006. View at Publisher · View at Google Scholar
  32. M. Letsch, A. V. Schally, K. Szepeshazi, G. Halmos, and A. Nagy, “Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers,” Clinical Cancer Research, vol. 9, no. 12, pp. 4505–4513, 2003. View at Google Scholar
  33. T. Karampelas, O. Argyros, N. Sayyad et al., “GnRH-gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery,” Bioconjugate Chemistry, vol. 25, no. 4, pp. 813–823, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. A. P. Kafka, T. Kleffmann, T. Rades, and A. Mcdowell, “Histidine residues in the peptide d-Lys6-GnRH: potential for copolymerization in polymeric nanoparticles,” Molecular Pharmaceutics, vol. 6, no. 5, pp. 1483–1491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Chen, G. Niu, H. Wu, and X. Chen, “Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3,” Theranostics, vol. 6, no. 1, pp. 78–92, 2016. View at Publisher · View at Google Scholar · View at Scopus